Dr MSIB - Tryp Therapeutics Pres CEO
| TRYPFDelisted Stock | USD 0.05 0 6.89% |
Insider
Dr MSIB is Pres CEO of Tryp Therapeutics
| Age | 71 |
| Phone | 833 811 8797 |
| Web | https://www.tryptherapeutics.com |
Tryp Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.0512) % which means that it has lost $2.0512 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (9.2206) %, meaning that it generated substantial loss on money invested by shareholders. Tryp Therapeutics' management efficiency ratios could be used to measure how well Tryp Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MSc MSc | Cellectis SA | 54 | |
| MEng CFA | Antibe Therapeutics | N/A | |
| Barry Kenny | Sosei Group | N/A | |
| Ana Stegic | Antibe Therapeutics | N/A | |
| Naoki Tsukahara | SanBio Company Limited | N/A | |
| Hironoshin Nomura | Sosei Group | N/A | |
| Greg Gillas | SanBio Company Limited | N/A | |
| Andrew Todd | Pharmather Holdings | 65 | |
| Miles Congreve | Sosei Group | N/A | |
| MBA MBA | Antibe Therapeutics | N/A | |
| Fabio Chianelli | Pharmather Holdings | 45 | |
| MBA DO | Antibe Therapeutics | 57 | |
| Kazuhiko Yoshizumi | Sosei Group | 69 | |
| Shinichiro Nishishita | Sosei Group | N/A | |
| Andrew Liu | SanBio Company Limited | N/A | |
| ACIS BComm | Pharmather Holdings | 51 | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| Kyung NamWortman | Cellectis SA | 53 | |
| MBA MSc | Antibe Therapeutics | 65 | |
| Valerie Cros | Cellectis SA | N/A | |
| Bijan Nejadnik | SanBio Company Limited | 61 | |
Management Performance
| Return On Equity | -9.22 | |||
| Return On Asset | -2.05 |
Tryp Therapeutics Leadership Team
Elected by the shareholders, the Tryp Therapeutics' board of directors comprises two types of representatives: Tryp Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tryp. The board's role is to monitor Tryp Therapeutics' management team and ensure that shareholders' interests are well served. Tryp Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tryp Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, CoFounder Director | ||
| Joy Willis, Director Relations | ||
| Dr MSIB, Pres CEO | ||
| Jim ONeill, Chief Officer | ||
| Sidney RPh, Chief Officer |
Tryp Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Tryp Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.22 | |||
| Return On Asset | -2.05 | |||
| Current Valuation | 4.17 M | |||
| Shares Outstanding | 96.42 M | |||
| Shares Owned By Insiders | 47.24 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Price To Book | 2.50 X | |||
| EBITDA | (7.36 M) | |||
| Net Income | (7.49 M) | |||
| Cash And Equivalents | 2.85 M |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Tryp OTC Stock
If you are still planning to invest in Tryp Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tryp Therapeutics' history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |